T1	Participants 138 193	Patients with acute exacerbations of chronic bronchitis
T2	Participants 347 395	548 patients enrolled, 281 (51%) were evaluable.
T3	Participants 491 545	evaluable patients treated with cefdinir and cefprozil
T4	Participants 1142 1224	patients treated with cefdinir (17%) than for patients treated with cefprozil (6%)
T5	Participants 1413 1421	patients
T6	Participants 1427 1468	acute exacerbations of chronic bronchitis
